Influenza and Viral Pneumonia

Clinics in Chest Medicine

Volumn 39, Issue 4, 2018, Pages 703-721

  Cavallazzi, Rodrigo ^a   Ramirez, Julio A ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

Author keywords

Antiviral; Epidemiology; Influenza; Pneumonia; Polymerase chain reaction; Symptoms; Virus

Indexed keywords

ACICLOVIR; AMANTADINE DERIVATIVE; CORTICOSTEROID; GANCICLOVIR; HYPERIMMUNE GLOBULIN; IMMUNOGLOBULIN; OSELTAMIVIR; PALIVIZUMAB; PERAMIVIR; RIBAVIRIN; SIALIDASE INHIBITOR; ZANAMIVIR;

ADENOVIRIDAE; CHICKENPOX; CLINICAL FEATURE; COMMUNITY ACQUIRED PNEUMONIA; CORONAVIRINAE; CYTOMEGALOVIRUS INFECTION; EPIDEMIC; EPIDEMIOLOGICAL DATA; HOSPITAL INFECTION; HUMAN; HUMAN BOCAVIRUS; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOCOMPROMISED PATIENT; INCIDENCE; INFECTION RISK; INFECTION SENSITIVITY; INFLUENZA; METAPNEUMOVIRUS; NAUSEA; NONHUMAN; PANDEMIC; PARAINFLUENZA VIRUS INFECTION; PNEUMONIA; PRIORITY JOURNAL; RADIOLOGICAL PARAMETERS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; REVIEW; RHINOVIRUS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY; TREATMENT INDICATION; TREATMENT WITHDRAWAL; VIRAL RESPIRATORY TRACT INFECTION; VIRUS GENOME; VIRUS IDENTIFICATION; VIRUS PNEUMONIA; VOMITING; COMMUNITY ACQUIRED INFECTION; FEMALE; MALE; PATHOLOGY;

COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; INFLUENZA, HUMAN; MALE; PNEUMONIA, VIRAL;

EID: 85055734312     PISSN: 02725231     EISSN: 15578216     Source Type: Journal    
DOI: 10.1016/j.ccm.2018.07.005     Document Type: Review

References (130)

1. Iuliano, A.D., Roguski, K.M., Chang, H.H., et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet 391:10127 (2017), 1285–1300.
2. Jain, S., Self, W.H., Wunderink, R.G., et al. Community-acquired pneumonia requiring hospitalization among U.S. adults. N Engl J Med 373:5 (2015), 415–427.
3. Horimoto, T., Kawaoka, Y., Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol 3:8 (2005), 591–600.
4. Zimmer, S.M., Burke, D.S., Historical perspective—emergence of influenza A (H1N1) viruses. N Engl J Med 361:3 (2009), 279–285.
5. De Clercq, E., Li, G., Approved antiviral drugs over the past 50 years. Clin Microbiol Rev 29:3 (2016), 695–747.
6. Blanton, L., Alabi, N., Mustaquim, D., et al. Update: influenza activity in the United States during the 2016-17 season and composition of the 2017-18 influenza vaccine. MMWR Morb Mortal Wkly Rep 66:25 (2017), 668–676.
7. Kamali, A., Holodniy, M., Influenza treatment and prophylaxis with neuraminidase inhibitors: a review. Infect Drug Resist 6 (2013), 187–198.
8. Bouvier, N.M., Palese, P., The biology of influenza viruses. Vaccine 26:Suppl 4 (2008), D49–D53.
9. McLellan, J.S., Ray, W.C., Peeples, M.E., Structure and function of respiratory syncytial virus surface glycoproteins. Curr Top Microbiol Immunol 372 (2013), 83–104.
10. Jacobs, S.E., Lamson, D.M., St George, K., et al. Human rhinoviruses. Clin Microbiol Rev 26:1 (2013), 135–162.
11. San Martin, C., Latest insights on adenovirus structure and assembly. Viruses 4:5 (2012), 847–877.
12. Henrickson, K.J., Parainfluenza viruses. Clin Microbiol Rev 16:2 (2003), 242–264.
13. de Haan, C.A., Kuo, L., Masters, P.S., et al. Coronavirus particle assembly: primary structure requirements of the membrane protein. J Virol 72:8 (1998), 6838–6850.
14. Wen, X., Krause, J.C., Leser, G.P., et al. Structure of the human metapneumovirus fusion protein with neutralizing antibody identifies a pneumovirus antigenic site. Nat Struct Mol Biol 19:4 (2012), 461–463.
15. Gurda, B.L., Parent, K.N., Bladek, H., et al. Human bocavirus capsid structure: insights into the structural repertoire of the Parvoviridae. J Virol 84:12 (2010), 5880–5889.
16. Melero, J.A., Mas, V., The Pneumovirinae fusion (F) protein: a common target for vaccines and antivirals. Virus Res 209 (2015), 128–135.
17. Thibaut, H.J., De Palma, A.M., Neyts, J., Combating enterovirus replication: state-of-the-art on antiviral research. Biochem Pharmacol 83:2 (2012), 185–192.
18. Olson, N.H., Kolatkar, P.R., Oliveira, M.A., et al. Structure of a human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci U S A 90:2 (1993), 507–511.
19. Burk, M., El-Kersh, K., Saad, M., et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev 25:140 (2016), 178–188.
20. Yin, Y.D., Zhao, F., Ren, L.L., et al. Evaluation of the Japanese respiratory society guidelines for the identification of mycoplasma pneumoniae pneumonia. Respirology 17:7 (2012), 1131–1136.
21. Choi, S.H., Hong, S.B., Ko, G.B., et al. Viral infection in patients with severe pneumonia requiring intensive care unit admission. Am J Respir Crit Care Med 186:4 (2012), 325–332.
22. Karhu, J., Ala-Kokko, T.I., Vuorinen, T., et al. Lower respiratory tract virus findings in mechanically ventilated patients with severe community-acquired pneumonia. Clin Infect Dis 59:1 (2014), 62–70.
23. Couch, R.B., Englund, J.A., Whimbey, E., Respiratory viral infections in immunocompetent and immunocompromised persons. Am J Med 102:3A (1997), 2–9 [discussion: 25–6].
24. Meyers, J.D., Flournoy, N., Thomas, E.D., Nonbacterial pneumonia after allogeneic marrow transplantation: a review of ten years’ experience. Rev Infect Dis 4:6 (1982), 1119–1132.
25. Kim, D.H., Messner, H., Minden, M., et al. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders. Transpl Infect Dis 10:2 (2008), 90–98.
26. Koc, Y., Miller, K.B., Schenkein, D.P., et al. Varicella zoster virus infections following allogeneic bone marrow transplantation: frequency, risk factors, and clinical outcome. Biol Blood Marrow Transplant 6:1 (2000), 44–49.
27. Green, M.L., Viral pneumonia in patients with hematopoietic cell transplantation and hematologic malignancies. Clin Chest Med 38:2 (2017), 295–305.
28. Hong, H.L., Hong, S.B., Ko, G.B., et al. Viral infection is not uncommon in adult patients with severe hospital-acquired pneumonia. PLoS One, 9(4), 2014, e95865.
29. Dawood, F.S., Iuliano, A.D., Reed, C., et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 12:9 (2012), 687–695.
30. Lee, N., Hui, D., Wu, A., et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 348:20 (2003), 1986–1994.
31. Ksiazek, T.G., Erdman, D., Goldsmith, C.S., et al. A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 348:20 (2003), 1953–1966.
32. Drosten, C., Gunther, S., Preiser, W., et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N Engl J Med 348:20 (2003), 1967–1976.
33. Zaki, A.M., van Boheemen, S., Bestebroer, T.M., et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 367:19 (2012), 1814–1820.
34. de Groot, R.J., Baker, S.C., Baric, R.S., et al. Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the coronavirus study group. J Virol 87:14 (2013), 7790–7792.
35. Lim, Y.X., Ng, Y.L., Tam, J.P., et al. Human coronaviruses: a review of virus-host interactions. Diseases, 4(3), 2016, 10.3390/diseases4030026.
36. Guery, B., Poissy, J., el Mansouf, L., et al. Clinical features and viral diagnosis of two cases of infection with Middle East respiratory syndrome coronavirus: a report of nosocomial transmission. Lancet 381:9885 (2013), 2265–2272.
37. Assiri, A., McGeer, A., Perl, T.M., et al. Hospital outbreak of Middle East respiratory syndrome coronavirus. N Engl J Med 369:5 (2013), 407–416.
38. Bialek, S.R., Allen, D., Alvarado-Ramy, F., et al. First confirmed cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection in the United States, updated information on the epidemiology of MERS-CoV infection, and guidance for the public, clinicians, and public health authorities - May 2014. MMWR Morb Mortal Wkly Rep 63:19 (2014), 431–436.
39. Chunara, R., Goldstein, E., Patterson-Lomba, O., et al. Estimating influenza attack rates in the United States using a participatory cohort. Sci Rep, 5, 2015, 9540.
40. Dao, C.N., Kamimoto, L., Nowell, M., et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2008 seasons in the United States. J Infect Dis 202:6 (2010), 881–888.
41. Casalino, E., Antoniol, S., Fidouh, N., et al. Influenza virus infections among patients attending emergency department according to main reason to presenting to ED: a 3-year prospective observational study during seasonal epidemic periods. PLoS One, 12(8), 2017, e0182191.
42. Garg, S., Jain, S., Dawood, F.S., et al. Pneumonia among adults hospitalized with laboratory-confirmed seasonal influenza virus infection—United States, 2005-2008. BMC Infect Dis, 15, 2015, 369.
43. Maruyama, T., Fujisawa, T., Suga, S., et al. Outcomes and prognostic features of patients with influenza requiring hospitalization and receiving early antiviral therapy: a prospective multicenter cohort study. Chest 149:2 (2016), 526–534.
44. Blanton, L., Mustaquim, D., Alabi, N., et al. Update: influenza activity—United States, October 2, 2016-February 4, 2017. MMWR Morb Mortal Wkly Rep 66:6 (2017), 159–166.
45. Falsey, A.R., Hennessey, P.A., Formica, M.A., et al. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med 352:17 (2005), 1749–1759.
46. Zhou, H., Thompson, W.W., Viboud, C.G., et al. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis 54:10 (2012), 1427–1436.
47. Gwaltney, J.M., Clinical significance and pathogenesis of viral respiratory infections. Am J Med 112:Suppl 6A (2002), 13S–18S.
48. Monto, A.S., The seasonality of rhinovirus infections and its implications for clinical recognition. Clin Ther 24:12 (2002), 1987–1997.
49. Gaunt, E.R., Hardie, A., Claas, E.C., et al. Epidemiology and clinical presentations of the four human coronaviruses 229E, HKU1, NL63, and OC43 detected over 3 years using a novel multiplex real-time PCR method. J Clin Microbiol 48:8 (2010), 2940–2947.
50. Gerna, G., Percivalle, E., Sarasini, A., et al. Human respiratory coronavirus HKU1 versus other coronavirus infections in Italian hospitalised patients. J Clin Virol 38:3 (2007), 244–250.
51. Ruuskanen, O., Mertsola, J., Meurman, O., Adenovirus infection in families. Arch Dis Child 63:10 (1988), 1250–1253.
52. Tan, D., Zhu, H., Fu, Y., et al. Severe community-acquired pneumonia caused by human adenovirus in immunocompetent adults: a multicenter case series. PLoS One, 11(3), 2016, e0151199.
53. Cao, B., Huang, G.H., Pu, Z.H., et al. Emergence of community-acquired adenovirus type 55 as a cause of community-onset pneumonia. Chest 145:1 (2014), 79–86.
54. Shields, A.F., Hackman, R.C., Fife, K.H., et al. Adenovirus infections in patients undergoing bone-marrow transplantation. N Engl J Med 312:9 (1985), 529–533.
55. Berciaud, S., Rayne, F., Kassab, S., et al. Adenovirus infections in Bordeaux University Hospital 2008-2010: clinical and virological features. J Clin Virol 54:4 (2012), 302–307.
56. Park, J.Y., Kim, B.J., Lee, E.J., et al. Clinical features and courses of adenovirus pneumonia in healthy young adults during an outbreak among Korean military personnel. PLoS One, 12(1), 2017, e0170592.
57. Klinger, J.R., Sanchez, M.P., Curtin, L.A., et al. Multiple cases of life-threatening adenovirus pneumonia in a mental health care center. Am J Respir Crit Care Med 157:2 (1998), 645–649.
58. Cassir, N., Hraiech, S., Nougairede, A., et al. Outbreak of adenovirus type 1 severe pneumonia in a French intensive care unit, September-October 2012. Euro Surveill, 19(39), 2014 [pii:20914].
59. Weinberg, G.A., Hall, C.B., Iwane, M.K., et al. Parainfluenza virus infection of young children: estimates of the population-based burden of hospitalization. J Pediatr 154:5 (2009), 694–699.
60. Liu, W.K., Liu, Q., Chen, D.H., et al. Epidemiology and clinical presentation of the four human parainfluenza virus types. BMC Infect Dis, 13, 2013, 28.
61. Marx, A., Gary, H.E. Jr., Marston, B.J., et al. Parainfluenza virus infection among adults hospitalized for lower respiratory tract infection. Clin Infect Dis 29:1 (1999), 134–140.
62. Falsey, A.R., Erdman, D., Anderson, L.J., et al. Human metapneumovirus infections in young and elderly adults. J Infect Dis 187:5 (2003), 785–790.
63. Johnstone, J., Majumdar, S.R., Fox, J.D., et al. Human metapneumovirus pneumonia in adults: results of a prospective study. Clin Infect Dis 46:4 (2008), 571–574.
64. Longtin, J., Bastien, M., Gilca, R., et al. Human bocavirus infections in hospitalized children and adults. Emerg Infect Dis 14:2 (2008), 217–221.
65. Ghietto, L.M., Majul, D., Ferreyra Soaje, P., et al. Comorbidity and high viral load linked to clinical presentation of respiratory human bocavirus infection. Arch Virol 160:1 (2015), 117–127.
66. Jula, A., Waris, M., Kantola, K., et al. Primary and secondary human bocavirus 1 infections in a family, Finland. Emerg Infect Dis 19:8 (2013), 1328–1331.
67. Mori, D., Ranawaka, U., Yamada, K., et al. Human bocavirus in patients with encephalitis, Sri Lanka, 2009-2010. Emerg Infect Dis 19:11 (2013), 1859–1862.
68. Yu, J.M., Chen, Q.Q., Hao, Y.X., et al. Identification of human bocaviruses in the cerebrospinal fluid of children hospitalized with encephalitis in China. J Clin Virol 57:4 (2013), 374–377.
69. Windisch, W., Schildgen, V., Malecki, M., et al. Detection of HBoV DNA in idiopathic lung fibrosis, cologne, Germany. J Clin Virol 58:1 (2013), 325–327.
70. Krakau, M., Brockmann, M., Titius, B., et al. Acute human bocavirus infection in MDS patient, Cologne, Germany. J Clin Virol 69 (2015), 44–47.
71. Falcone, V., Ridder, G.J., Panning, M., et al. Human bocavirus DNA in paranasal sinus mucosa. Emerg Infect Dis 17:8 (2011), 1564–1565.
72. Stein, J., Louie, J., Flanders, S., et al. Performance characteristics of clinical diagnosis, a clinical decision rule, and a rapid influenza test in the detection of influenza infection in a community sample of adults. Ann Emerg Med 46:5 (2005), 412–419.
73. Oliveira, E.C., Marik, P.E., Colice, G., Influenza pneumonia: a descriptive study. Chest 119:6 (2001), 1717–1723.
74. Michiels, B., Thomas, I., Van Royen, P., et al. Clinical prediction rules combining signs, symptoms and epidemiological context to distinguish influenza from influenza-like illnesses in primary care: a cross sectional study. BMC Fam Pract, 12, 2011, 4.
75. Ebell, M.H., Afonso, A., A systematic review of clinical decision rules for the diagnosis of influenza. Ann Fam Med 9:1 (2011), 69–77.
76. Boivin, G., Hardy, I., Tellier, G., et al. Predicting influenza infections during epidemics with use of a clinical case definition. Clin Infect Dis 31:5 (2000), 1166–1169.
77. Dugas, A.F., Valsamakis, A., Atreya, M.R., et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med 33:6 (2015), 770–775.
78. McGee, S., Simplifying likelihood ratios. J Gen Intern Med 17:8 (2002), 646–649.
79. Saha, S., Chadha, M., Al Mamun, A., et al. Influenza seasonality and vaccination timing in tropical and subtropical areas of southern and south-eastern Asia. Bull World Health Organ 92:5 (2014), 318–330.
80. Walsh, E.E., Peterson, D.R., Falsey, A.R., Is clinical recognition of respiratory syncytial virus infection in hospitalized elderly and high-risk adults possible?. J Infect Dis 195:7 (2007), 1046–1051.
81. Dowell, S.F., Anderson, L.J., Gary, H.E. Jr., et al. Respiratory syncytial virus is an important cause of community-acquired lower respiratory infection among hospitalized adults. J Infect Dis 174:3 (1996), 456–462.
82. Huijskens, E.G., Koopmans, M., Palmen, F.M., et al. The value of signs and symptoms in differentiating between bacterial, viral and mixed aetiology in patients with community-acquired pneumonia. J Med Microbiol 63:Pt 3 (2014), 441–452.
83. Heckerling, P.S., Tape, T.G., Wigton, R.S., et al. Clinical prediction rule for pulmonary infiltrates. Ann Intern Med 113:9 (1990), 664–670.
84. Aviram, G., Bar-Shai, A., Sosna, J., et al. H1N1 influenza: initial chest radiographic findings in helping predict patient outcome. Radiology 255:1 (2010), 252–259.
85. Woo, P.C., Lau, S.K., Tsoi, H.W., et al. Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia. J Infect Dis 192:11 (2005), 1898–1907.
86. Chong, S., Lee, K.S., Kim, T.S., et al. Adenovirus pneumonia in adults: radiographic and high-resolution CT findings in five patients. AJR Am J Roentgenol 186:5 (2006), 1288–1293.
87. Wang, K., Xi, W., Yang, D., et al. Rhinovirus is associated with severe adult community-acquired pneumonia in China. J Thorac Dis 9:11 (2017), 4502–4511.
88. Moscona, A., Neuraminidase inhibitors for influenza. N Engl J Med 353:13 (2005), 1363–1373.
89. Wang, C., Takeuchi, K., Pinto, L.H., et al. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol 67:9 (1993), 5585–5594.
90. Available at: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm. Accessed January 13, 2018.
91. Jefferson, T., Jones, M., Doshi, P., et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ, 348, 2014, g2545.
92. Hsu, J., Santesso, N., Mustafa, R., et al. Antivirals for treatment of influenza: a systematic review and meta-analysis of observational studies. Ann Intern Med 156:7 (2012), 512–524.
93. Biggerstaff, M., Jhung, M.A., Reed, C., et al. Impact of medical and behavioural factors on influenza-like illness, healthcare-seeking, and antiviral treatment during the 2009 H1N1 pandemic: USA, 2009-2010. Epidemiol Infect 142:1 (2014), 114–125.
94. Lindegren, M.L., Schaffner, W., Treatment with neuraminidase inhibitors for high-risk patients with influenza: why is adherence to antiviral treatment recommendations so low?. J Infect Dis 210:4 (2014), 510–513.
95. Louie, J.K., Yang, S., Acosta, M., et al. Treatment with neuraminidase inhibitors for critically ill patients with influenza A (H1N1)pdm09. Clin Infect Dis 55:9 (2012), 1198–1204.
96. Kim, S.J., Kim, K., Park, S.B., et al. Outcomes of early administration of cidofovir in non-immunocompromised patients with severe adenovirus pneumonia. PLoS One, 10(4), 2015, e0122642.
97. Lee, M., Kim, S., Kwon, O.J., et al. Treatment of adenoviral acute respiratory distress syndrome using cidofovir with extracorporeal membrane oxygenation. J Intensive Care Med 32:3 (2017), 231–238.
98. Grilli, E., Galati, V., Bordi, L., et al. Cytomegalovirus pneumonia in immunocompetent host: case report and literature review. J Clin Virol 55:4 (2012), 356–359.
99. Hunt, D.P., Muse, V.V., Pitman, M.B., Case records of the Massachusetts General Hospital. Case 12-2013. An 18-year-old woman with pulmonary infiltrates and respiratory failure. N Engl J Med 368:16 (2013), 1537–1545.
100. Broussard, R.C., Payne, D.K., George, R.B., Treatment with acyclovir of varicella pneumonia in pregnancy. Chest 99:4 (1991), 1045–1047.
101. Khanna, N., Widmer, A.F., Decker, M., et al. Respiratory syncytial virus infection in patients with hematological diseases: single-center study and review of the literature. Clin Infect Dis 46:3 (2008), 402–412.
102. Tan, B.H., Cytomegalovirus treatment. Curr Treat Options Infect Dis 6:3 (2014), 256–270.
103. Reed, E.C., Bowden, R.A., Dandliker, P.S., et al. Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:10 (1988), 783–788.
104. Farthing, C., Anderson, M.G., Ellis, M.E., et al. Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. J Med Virol 22:2 (1987), 157–162.
105. Mohsen, A.H., McKendrick, M., Varicella pneumonia in adults. Eur Respir J 21:5 (2003), 886–891.
106. Ferrari, A., Luppi, M., Potenza, L., et al. Herpes simplex virus pneumonia during standard induction chemotherapy for acute leukemia: case report and review of literature. Leukemia 19:11 (2005), 2019–2021.
107. Yee, C., Suarthana, E., Dendukuri, N., et al. Evaluating the impact of the multiplex respiratory virus panel polymerase chain reaction test on the clinical management of suspected respiratory viral infections in adult patients in a hospital setting. Am J Infect Control 44:11 (2016), 1396–1398.
108. Schuetz, P., Wirz, Y., Sager, R., et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev(10), 2017 CD007498.
109. Branche, A.R., Walsh, E.E., Vargas, R., et al. Serum procalcitonin measurement and viral testing to guide antibiotic use for respiratory infections in hospitalized adults: a randomized controlled trial. J Infect Dis 212:11 (2015), 1692–1700.
110. Timbrook, T., Maxam, M., Bosso, J., Antibiotic discontinuation rates associated with positive respiratory viral panel and low procalcitonin results in proven or suspected respiratory infections. Infect Dis Ther 4:3 (2015), 297–306.
111. Brendish, N.J., Malachira, A.K., Armstrong, L., et al. Routine molecular point-of-care testing for respiratory viruses in adults presenting to hospital with acute respiratory illness (ResPOC): a pragmatic, open-label, randomised controlled trial. Lancet Respir Med 5:5 (2017), 401–411.
112. Siemieniuk, R.A., Meade, M.O., Alonso-Coello, P., et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med 163:7 (2015), 519–528.
113. Torres, A., Sibila, O., Ferrer, M., et al. Effect of corticosteroids on treatment failure among hospitalized patients with severe community-acquired pneumonia and high inflammatory response: a randomized clinical trial. JAMA 313:7 (2015), 677–686.
114. Cavallazzi, R., Ramirez, J.A., Using steroids in patients with community-acquired pneumonia at the university of Louisville Hospital: who, what, and when. Univ Louisville J Respir Infect 1:4 (2017), 4–6.
115. Brun-Buisson, C., Richard, J.C., Mercat, A., et al., REVA-SRLF A/H1N1v 2009 Registry Group. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med 183:9 (2011), 1200–1206.
116. Annane, D., Antona, M., Lehmann, B., et al. Designing and conducting a randomized trial for pandemic critical illness: the 2009 H1N1 influenza pandemic. Intensive Care Med 38:1 (2012), 29–39.
117. Rodrigo, C., Leonardi-Bee, J., Nguyen-Van-Tam, J.S., et al. Effect of corticosteroid therapy on influenza-related mortality: a systematic review and meta-analysis. J Infect Dis 212:2 (2015), 183–194.
118. Somerville, L.K., Ratnamohan, V.M., Dwyer, D.E., et al. Molecular diagnosis of respiratory viruses. Pathology 47:3 (2015), 243–249.
119. Pires de Mello, C.P., Drusano, G.L., Adams, J.R., et al. Oseltamivir-zanamivir combination therapy suppresses drug-resistant H1N1 influenza A viruses in the hollow fiber infection model (HFIM) system. Eur J Pharm Sci 111 (2018), 443–449.
120. Duval, X., van der Werf, S., Blanchon, T., et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med, 7(11), 2010, e1000362.
121. Hung, I.F.N., To, K.K.W., Chan, J.F.W., et al. Efficacy of clarithromycin-naproxen-oseltamivir combination in the treatment of patients hospitalized for influenza A(H3N2) infection: an open-label randomized, controlled, phase IIb/III trial. Chest 151:5 (2017), 1069–1080.
122. Nguyen, J.T., Hoopes, J.D., Le, M.H., et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One, 5(2), 2010, e9332.
123. Smee, D.F., Hurst, B.L., Wong, M.H., et al. Effects of double combinations of amantadine, oseltamivir, and ribavirin on influenza A (H5N1) virus infections in cell culture and in mice. Antimicrob Agents Chemother 53:5 (2009), 2120–2128.
124. DeVincenzo, J.P., Whitley, R.J., Mackman, R.L., et al. Oral GS-5806 activity in a respiratory syncytial virus challenge study. N Engl J Med 371:8 (2014), 711–722.
125. DeVincenzo, J.P., McClure, M.W., Symons, J.A., et al. Activity of oral ALS-008176 in a respiratory syncytial virus challenge study. N Engl J Med 373:21 (2015), 2048–2058.
126. Self, W.H., Williams, D.J., Zhu, Y., et al. Respiratory viral detection in children and adults: comparing asymptomatic controls and patients with community-acquired pneumonia. J Infect Dis 213:4 (2016), 584–591.
127. Korteweg, C., Gu, J., Pathology, molecular biology, and pathogenesis of avian influenza A (H5N1) infection in humans. Am J Pathol 172:5 (2008), 1155–1170.
128. van der Sluijs, K.F., van der Poll, T., Lutter, R., et al. Bench-to-bedside review: bacterial pneumonia with influenza—pathogenesis and clinical implications. Crit Care, 14(2), 2010, 219.
129. Grabowska, K., Hogberg, L., Penttinen, P., et al. Occurrence of invasive pneumococcal disease and number of excess cases due to influenza. BMC Infect Dis, 6, 2006, 58.
130. Jartti, T., Lehtinen, P., Vuorinen, T., et al. Persistence of rhinovirus and enterovirus RNA after acute respiratory illness in children. J Med Virol 72:4 (2004), 695–699.